Are Serial BNP Measurements Useful in Heart Failure Management?: Serial Natriuretic Peptide Measurements Are Not Useful in Heart Failure Management The Art of Medicine Remains Long

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Circulation

• Publication date

  2013-01-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.112.120493PMID 23357663
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes.

  2011cited by this paper
• Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus

  2011cited by this paper
• The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure.

  2011cited by this paper
• Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.

  2011cited by this paper
• N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.

  2010cited by this paper
• Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study.

  2010cited by this paper
• Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT‐proBNP Guided Management of Heart Failure – SIGNAL‐HF (Swedish Intervention study – Guidelines and NT‐proBNP AnaLysis in Heart Failure)

  2010cited by this paper
• Effects of intensive blood-pressure control in type 2 diabetes mellitus.

  2010cited by this paper
• Biomarker-guided treatment of heart failure: still waiting for a definitive answer.

  2010cited by this paper
• Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score.

  2010cited by this paper
• N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.

  2009cited by this paper
• Loop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil?

  2009cited by this paper
• Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).

  2009cited by this paper
• Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure

  2009cited by this paper
• BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.

  2009cited by this paper
• Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.

  2009cited by this paper
• Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings From IMPROVE HF

  2008cited by this paper
• Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial).

  2008cited by this paper
• Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.

  2008cited by this paper
• National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure.

  2008cited by this paper
• National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure.

  2007cited by this paper
• Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.

  2007cited by this paper
• Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels.

  2007cited by this paper
• Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

  2007cited by this paper
• Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.

  2007cited by this paper
• Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.

  2006cited by this paper
• Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.

  2006cited by this paper
• Long-term clinical variation of NT-proBNP in stable chronic heart failure patients.

  2006cited by this paper
• Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.

  2006cited by this paper
• Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department.

  2006cited by this paper
• Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.

  2006cited by this paper
• Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study

  2005cited by this paper
• How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review

  2005cited by this paper
• The effect of cardiac resynchronization on morbidity and mortality in heart failure.

  2005cited by this paper
• The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.

  2005cited by this paper
• Optimal Noninvasive Assessment of Left Ventricular Filling Pressures: A Comparison of Tissue Doppler Echocardiography and B-Type Natriuretic Peptide in Patients With Pulmonary Artery Catheters

  2004cited by this paper
• Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial

  2004cited by this paper
• Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure.

  2004cited by this paper
• Impact of Obesity on Plasma Natriuretic Peptide Levels

  2004cited by this paper
• N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients

  2004cited by this paper
• The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

  2004cited by this paper
• Plasma B-Type Natriuretic Peptide Levels in Ambulatory Patients With Established Chronic Symptomatic Systolic Heart Failure

  2003cited by this paper
• Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)

  2003cited by this paper
• Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure?

  2003cited by this paper
• Heart failure/transplant: abstractEffects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)☆

  2003cited by this paper
• Should B-Type Natriuretic Peptide Be Measured Routinely to Guide the Diagnosis and Management of Chronic Heart Failure?

  2003cited by this paper
• Impact of age and sex on plasma natriuretic peptide levels in healthy adults.

  2002cited by this paper
• Plasma brain natriuretic peptide concentration: impact of age and gender.

  2002cited by this paper
• The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure.

  2002cited by this paper
• Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT)

  2002cited by this paper
• Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.

  2001cited by this paper
• Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

  2001cited by this paper
• Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

  2000cited by this paper
• Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia.

  1994cited by this paper
• Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction.

  1993cited by this paper
• Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.

  1986cited by this paper

• Circulating Biomarkers in Elderly Patients with Heart Failure: A Real-Life Study

  2026cites this paper
• A comprehensive review of inpatient heart failure management for the hospitalist

  2025cites this paper
• Loop diuretic down‐titration at discharge in patients hospitalized for acute heart failure

  2024cites this paper
• Biomarkers in heart failure: Relevance in the clinical practice.

  2022cites this paper
• Role of Pocket Ultrasound in Assessing Intravascular Volume to Guide Management in Heart Failure Patients with Renal Impairment

  2021cites this paper
• Milrinone is better choice for controlled low central venous pressure during hepatectomy: A randomized, controlled trial comparing with nitroglycerin.

  2021cites this paper
• Biomarkers in Heart Failure: Clinical Insights.

  2021cites this paper
• Silver Nanocubes as Electrochemical Labels for Bioassays.

  2021cites this paper
• A randomized controlled trial of the effects of non-surgical periodontal therapy on cardiac function assessed by echocardiography in type 2 diabetic patients.

  2020cites this paper
• Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure

  2020cites this paper
• Percutaneous mitral valve repair for secondary mitral valve regurgitation: A systematic review and meta-analysis.

  2020cites this paper
• Clinical and Biochemical Assessments of Circulating B-Type Natriuretic Peptide as a Useful Marker in Pediatric Cardiac Patients

  2020cites this paper
• Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT‐CHF

  2020cites this paper
• B-Type Natriuretic Peptides (BNP) and Tissue Doppler E/e´ Before and After 4 Weeks Standard Treatment of African Heart Failure Subjects: The ABU-BNP Longitudinal Survey

  2019cites this paper
• Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigation

  2019cites this paper
• Loop diuretic resistance complicating acute heart failure

  2019cites this paper
• The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology

  2019cites this paper
• Current Role of the CardioMEMS Device for Management of Patients with Heart Failure

  2019cites this paper
• The Authors Reply.

  2018cites this paper
• IL-33 (Interleukin 33)/sST2 Axis in Hypertension and Heart Failure.

  2018cites this paper
• Elevated serum uric acid concentration at discharge confers additive prognostic value in elderly patients with acute heart failure.

  2018cites this paper
• The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study

  2018cites this paper
• IL-33 ( Interleukin 33 ) / sST 2 ( Soluble Suppression of Tumorigenicity 2 ) Axis in Hypertension and Heart Failure

  2018cites this paper
• Longitudinal profile of NT-proBNP levels in ischemic heart failure patients undergoing surgical ventricular reconstruction: The Biomarker Plus study.

  2018cites this paper
• Managing Heart Failure at Home With Point-of-Care Diagnostics

  2017cites this paper
• Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF

  2017cites this paper
• Redefining the role of biomarkers in heart failure trials: expert consensus document

  2017cites this paper
• Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure

  2017cites this paper
• Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.

  2017cites this paper
• N-terminal pro-B-type natriuretic peptide in amniotic fluid of fetuses with known or suspected cardiac load

  2017cites this paper
• Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure

  2017cites this paper
• Reply to ‘Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure’

  2017cites this paper
• Acute Decompensated Heart Failure: Treatment – Specific Therapies

  2017cites this paper
• Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Effic

  2017cites this paper
• Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials

  2016cites this paper
• CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study

  2016cites this paper
• Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure

  2016cites this paper
• Clinical Cardiovascular Proteomics

  2016cites this paper
• Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients.

  2016cites this paper
• Dynamics of Biochemical Markers in Patients Suffering from Heart Failure under the Influence of Cell Therapy

  2015cites this paper
• 73-year-old man with dyspnea on exertion.

  2015cites this paper
• Clinical Applications of Natriuretic Peptides in Assessment of Valvular Heart Disease

  2015cites this paper
• Pharmacotherapy in heart failure with reduced ejection fraction during the last 20 years, and the way ahead for precision medicine.

  2015cites this paper
• Preprocedural N‐Terminal Pro‐Brain Natriuretic Peptide (NT‐proBNP) Is Similar to the Mehran Contrast‐Induced Nephropathy (CIN) Score in Predicting CIN Following Elective Coronary Angiography

  2015cites this paper
• Serial Measurement of Amino-Terminal Pro-B-Type Natriuretic Peptide Predicts Adverse Cardiovascular Outcome in Children With Primary Myocardial Dysfunction and Acute Decompensated Heart Failure

  2015cites this paper
• B-Type Natriuretic Peptide–Guided Therapy and Length of Hospital Stay Post Left Ventricular Assist Device Implantation

  2015cites this paper
• Understanding and making good use of changes in natriuretic peptide levels in chronic heart failure

  2015cites this paper
• Is B-type natriuretic peptide a risk factor for heart failure in patients treated with bardoxolone methyl?

  2015cites this paper
• Reference Intervals for N-Terminal Pro-B-Type Natriuretic Peptide in Amniotic Fluid between 10 and 34 Weeks of Gestation

  2014cites this paper
• Old tool – new application: NT‐proBNP in fetal medicine

  2014cites this paper
• The potential value of integrated natriuretic peptide and echo-guided heart failure management

  2014cites this paper
• Biomarkers: Heart Failure

  2014cites this paper
• Biomarcadores BNP e NT-proBNP na insuficiência cardíaca: revisão de literatura

  2014cites this paper
• Biomarkers in heart failure.

  2014cites this paper
• GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction: Design and Rationale for the Functional Impact of GLP-1 for Heart Failure Treatment Study

  2014cites this paper
• Charting a roadmap for heart failure biomarker studies.

  2014cites this paper
• Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin

  2014cites this paper
• Therapeutic Implications of Biomarkers in Chronic Heart Failure

  2013cites this paper
• Circulating Biomarkers in Patients with Heart Failure and Preserved Ejection Fraction

  2013cites this paper